Pharma Pursues Generic Injectables Quality Turnaround Opportunities
This article was originally published in The Gold Sheet
Executive Summary
Pfizer’s plan to acquire Hospira is part of a turnaround trend in which Big Pharma hopes its quality will rub off on the troubled generics injectables sector. The question is: Will it work?